Bristol-myers Squibb Company Profile
What is the competitive landscape for BRISTOL-MYERS SQUIBB
BRISTOL-MYERS SQUIBB has one approved drug.
There are five US patents protecting BRISTOL-MYERS SQUIBB drugs.
Summary for Bristol-myers Squibb
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Bristol-myers Squibb: | See patent lawsuits for Bristol-myers Squibb |
| PTAB Cases with Bristol-myers Squibb as patent owner: | See PTAB cases with Bristol-myers Squibb as patent owner |
Drugs and US Patents for Bristol-myers Squibb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | 8,329,159 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-003 | Apr 13, 2016 | DISCN | Yes | No | 9,421,192 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-001 | Jul 24, 2015 | DISCN | Yes | No | 8,629,171 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | 8,642,025 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | 8,629,171 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Bristol-myers Squibb Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20160410 | ⤷ Start Trial |
| Hungary | S1500008 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2009020828 | ⤷ Start Trial |
| Israel | 196813 | ⤷ Start Trial |
| Mexico | 2009001426 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol-myers Squibb Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2049522 | 122015000009 | Germany | ⤷ Start Trial | PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822 |
| 2049522 | 300713 | Netherlands | ⤷ Start Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
| 2049522 | SPC/GB15/003 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826 |
| 2049522 | C20150003 00128 | Estonia | ⤷ Start Trial | PRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014 |
| 2049522 | 9/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

